SLC2A5

Across TCGA pan-cancer cohorts, SLC2A5 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SLC2A5’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SLC2A5 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC2A5 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

LSCC, LUAD, and PDAC are the cancer types where SLC2A5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC2A5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	II,III,IV	+1.597	<.001	9	view →
LUAD	Male	All	+0.551	<.001	5	view →
PDAC	Female	All	+0.607	.014	4	view →
CCRCC	Male	All	−0.443	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SLC2A5–LSCC

Open the LSCC breakdown →